Aug 26 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
The approval was based on a study of 500 adults with previously treated metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer. The drug improved the rate of overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
Revolution Medicines did not immediately respond to a Reuters request for comment on pricing and availability.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Devika Syamnath)
